Ritter Pharmaceuticals Inc (RTTR)

[Werbe]

LOS ANGELES, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan will be the subject of an expert call to be held on February 20, 2019 at 1:00 PM ET/10:00 AM PT.

The call can be accessed via the following link: https://slingshotinsights.com/projects/965

Dr. Chey will be discussing:

The unmet medical need and target population for a potential pharmaceutical grade treatment of lactose intolerance (LI)
How LI is diagnosed in practice, the shortcomings of current treatment options and the role the microbiome plays in LI and the mechanism of action of RP-G28.

Insights regarding the ongoing, phase 3 clinical trial of RP-G28 including his thoughts on trial design, treatment benefit assessment and probability of success.

Ritter Pharmaceuticals expects to achieve major milestones in 2019, including the completion and data readout of its first pivotal phase 3 trial in lactose intolerance which is expected in the second half of 2019. In December 2018, the Company announced that it had reached the halfway-mark for enrollment in this trial. The 525-subject multicenter, randomized, double-blind, placebo-controlled, parallel-group study continues to enroll on-time. Persons interested in participating in the Liberatus study may receive more information by visiting www.clinicaltrials.gov (NCT03597516) or by visiting www.liberatusstudy.com/clinical-research.